Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of Enjuvia 0.3 mg for vulvar and vaginal atrophy due to menopause has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause
• Vulvar and Vaginal Atrophy

Drugs mentioned

• Enjuvia (conjugated estrogens)

Snippet

Sponsor: Duramed Research | Conditions: Menopause | Phase 3 | Status: COMPLETED